

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Patrys Limited
ABN	97 123 055 363

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Read
Date of last notice	14 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Suzannah Read 916,895 ordinary shares Harrison Read 916,895 ordinary shares Linda Greenhow 125,077 ordinary shares Cannington Corporation Pty Ltd 6,432,716 ordinary shares and 396,132 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023 The Director has the ability to influence the voting and disposal of these shares and options.
Date of change	5 August 2020

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p><u>Direct:</u> 518,723 ordinary shares 6,000,000 Unlisted options, exercisable at \$0.035, expiring on 22 November 2023</p> <p><u>Indirect:</u> Suzannah Read 916,895 ordinary shares, Harrison Read 916,895 ordinary shares, Linda Greenhow 125,077 ordinary shares, Cannington Corporation Pty Ltd 5,244,321 ordinary shares</p>
Class	<ul style="list-style-type: none"> - Ordinary shares - PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023
Number acquired	<ul style="list-style-type: none"> - 1,188,395 Ordinary shares - 396,132 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$14,260.74
No. of securities held after change	<p><u>Direct:</u> 518,723 ordinary shares 6,000,000 Unlisted options exercisable at \$0.035, expiring on 22 November 2023</p> <p><u>Indirect:</u> Suzannah Read 916,895 ordinary shares, Harrison Read 916,895 ordinary shares, Linda Greenhow 125,077 ordinary shares, Cannington Corporation Pty Ltd 6,432,716 ordinary shares and 396,132 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Sub-underwriting of Entitlement Offer

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Patrys Limited
ABN	97 123 055 363

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Campbell
Date of last notice	14 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Barrabool Biotechnology Pty Ltd <J and K Campbell Family A/C> Dr. Campbell is a beneficiary of the above entity
Date of change	5 August 2020
No. of securities held prior to change	<u>Direct:</u> 29,546 Fully paid ordinary shares 15,000,000 Unlisted options, exercisable at \$0.0072, expiring on 24 November 2021 10,000,000 Unlisted options, exercisable at \$0.035, expiring on 22 November 2023
Class	<ul style="list-style-type: none">- Fully paid ordinary shares- PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	<p>(1) <u>Direct:</u></p> <ul style="list-style-type: none"> - 9,849 Fully paid ordinary shares - 3,283 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023 <p>(2) <u>Indirect:</u></p> <ul style="list-style-type: none"> - 1,188,395 Fully paid ordinary shares - 396,132 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023
Number disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>(1) \$118.19</p> <p>(2) \$14,260.74</p>
No. of securities held after change	<p><u>Direct:</u></p> <p>39,395 Fully paid ordinary shares</p> <p>3,283 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023</p> <p>15,000,000 Unlisted options, exercisable at \$0.0072, expiring on 24 November 2021</p> <p>10,000,000 Unlisted options, exercisable at \$0.035, expiring on 22 November 2023</p> <p><u>Indirect:</u></p> <p>1,188,395 Fully paid ordinary shares</p> <p>396,132 PABO Listed options, exercisable at \$0.024 (2.4 cents), expiring 5 August 2023</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in and Sub-underwriting of Entitlement Offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.